- Home
- ACA vs RYTM Comparison
ACA vs RYTM Comparison
Compare ACA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACA | RYTM |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ACA | RYTM |
|---|---|---|
| Price | $117.52 | $108.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $117.50 | ★ $129.92 |
| AVG Volume (30 Days) | 209.3K | ★ 596.8K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 14.96 | N/A |
| EPS | ★ 3.02 | N/A |
| Revenue | ★ $2,832,900,000.00 | $174,334,000.00 |
| Revenue This Year | $13.39 | $47.78 |
| Revenue Next Year | $5.97 | $56.52 |
| P/E Ratio | $38.49 | ★ N/A |
| Revenue Growth | 13.96 | ★ 54.92 |
| 52 Week Low | $68.11 | $45.91 |
| 52 Week High | $118.84 | $122.20 |
Technical Indicators
Market Signals| Indicator | ACA | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 53.83 |
| Support Level | $112.64 | $100.59 |
| Resistance Level | $115.38 | $105.95 |
| Average True Range (ATR) | 2.82 | 5.31 |
| MACD | 0.07 | 0.42 |
| Stochastic Oscillator | 80.14 | 60.66 |
Price Performance
Historical ComparisonAbout ACA Arcosa Inc.
Arcosa Inc is a manufacturer and producer of infrastructure-related products and services. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment produces and sells construction aggregates and manufactures and sells trench shields and shoring products and services for infrastructure-related projects. The Transportation Products segment manufactures and sells products for the inland waterway and rail transportation industries. The Engineered Structures segment manufactures and sells products for energy-related businesses, including structural wind towers, telecommunication structures, steel utility structures for electricity transmission and distribution, and storage and distribution containers.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.